title: Ten years on: the impact of biologics on the practice of dermatology.
abstract: This review delivers a commentary on the first decade of biologics' use in psoriasis and provides a glimpse of the pipeline of therapies currently in development for psoriasis that will enhance the therapeutic armamentarium available to the dermatologist. In addition, the authors revisit the rationale for the development of biological therapies, inventory the available therapies of today, and retrospectively assess their impact on the dermatology practice as it relates to the management of patients with psoriasis.
authors.affiliation: Saint Louis University School of Medicine, 1034 South Brentwood Boulevard, Suite 600, St Louis, MO 63117-1206, USA. Electronic address: Craig.leonardi@centralderm.com.
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
authors.affiliation: University of São Paulo, São Paulo, Brazil.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Romiti
authors.affiliation: International Psoriasis Council, St Louis, MO, USA.
authors.forename: Paul W
authors.initials: PW
authors.lastname: Tebbey
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001691:Biological Therapy / Q000639:trends*; D003880:Dermatology / Q000639:trends*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology; D011788:Quality of Life; D013601:T-Lymphocytes / Q000187:drug effects; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha
keywords: Biologics; Clinical trials; Cytokines; Efficacy; Monoclonal antibodies; Psoriasis; Quality of life; Safety